Literature DB >> 32950386

Computerized tomography scan in pre-diagnostic pancreatic ductal adenocarcinoma: Stages of progression and potential benefits of early intervention: A retrospective study.

Dhruv Pratap Singh1, Shannon Sheedy2, Ajit H Goenka3, Michael Wells4, Nam Ju Lee5, John Barlow6, Ayush Sharma7, Harika Kandlakunta8, Shruti Chandra9, Sushil Kumar Garg10, Shounak Majumder11, Michael J Levy12, Naoki Takahashi13, Suresh T Chari14.   

Abstract

BACKGROUND: The frequency, nature and timeline of changes on thin-slice (≤3 mm) multi-detector computerized tomography (CT) scans in the pre-diagnostic phase of pancreatic ductal adenocarcinoma (PDAC) are unknown. It is unclear if identifying imaging changes in this phase will improve PDAC survival beyond lead time.
METHODS: From a cohort of 128 subjects (Cohort A) with CT scans done 3-36 months before diagnosis of PDAC we developed a CTgram defining CT Stages (CTS) I through IV in the radiological progression of pre-diagnostic PDAC. We constructed Cohort B of PDAC resected at CTS I and II and compared survival in CTS I and II in Cohort A (n = 22 each; control natural history cohort) vs Cohort B (n = 33 and 72, respectively; early interception cohort).
RESULTS: CTs were abnormal in 16% and 85% at 24-36 and 3-6 months respectively, before PDAC diagnosis. The PDAC CTgram stages, findings and median lead times (months) to clinical diagnosis were: CTS I: Abrupt duct cut-off/duct dilatation (-12.8); CTS II: Low density mass confined to pancreas (-9.5), CTS III: Peri-pancreatic infiltration (-5.8), CTS IV: Distant metastases (only at diagnosis). PDAC survival was better in cohort B than in cohort A despite inclusion of lead time in Cohort A: CTS I (36 vs 17.2 months, p = 0.03), CTS II (35.2 vs 15.3 months, p = 0.04).
CONCLUSION: Starting 12-18 months before PDAC diagnosis, progressive and increasingly frequent changes occur on CT scans. Resection of PDAC at the time of pre-diagnostic CT changes is likely to provide survival benefit beyond lead time.
Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CT timeline; Early detection; Lead time; Pancreatic ductal adenocarcinoma

Year:  2020        PMID: 32950386     DOI: 10.1016/j.pan.2020.07.410

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma.

Authors:  Suresh T Chari; Anirban Maitra; Lynn M Matrisian; Eva E Shrader; Bechien U Wu; Avinash Kambadakone; Ying-Qi Zhao; Barbara Kenner; Jo Ann S Rinaudo; Sudhir Srivastava; Ying Huang; Ziding Feng
Journal:  Contemp Clin Trials       Date:  2021-12-23       Impact factor: 2.226

Review 2.  Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.

Authors:  Barbara Kenner; Suresh T Chari; David Kelsen; David S Klimstra; Stephen J Pandol; Michael Rosenthal; Anil K Rustgi; James A Taylor; Adam Yala; Noura Abul-Husn; Dana K Andersen; David Bernstein; Søren Brunak; Marcia Irene Canto; Yonina C Eldar; Elliot K Fishman; Julie Fleshman; Vay Liang W Go; Jane M Holt; Bruce Field; Ann Goldberg; William Hoos; Christine Iacobuzio-Donahue; Debiao Li; Graham Lidgard; Anirban Maitra; Lynn M Matrisian; Sung Poblete; Laura Rothschild; Chris Sander; Lawrence H Schwartz; Uri Shalit; Sudhir Srivastava; Brian Wolpin
Journal:  Pancreas       Date:  2021-03-01       Impact factor: 3.243

Review 3.  Setting the Research Agenda for Clinical Artificial Intelligence in Pancreatic Adenocarcinoma Imaging.

Authors:  Megan Schuurmans; Natália Alves; Pierpaolo Vendittelli; Henkjan Huisman; John Hermans
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

4.  Fully Automatic Deep Learning Framework for Pancreatic Ductal Adenocarcinoma Detection on Computed Tomography.

Authors:  Natália Alves; Megan Schuurmans; Geke Litjens; Joeran S Bosma; John Hermans; Henkjan Huisman
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.